Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CEO Sujal M. Patel Buys 53,300 Shares

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CEO Sujal M. Patel bought 53,300 shares of the firm’s stock in a transaction dated Wednesday, March 19th. The shares were acquired at an average price of $0.99 per share, with a total value of $52,767.00. Following the completion of the transaction, the chief executive officer now owns 10,117,788 shares of the company’s stock, valued at approximately $10,016,610.12. The trade was a 0.53 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Nautilus Biotechnology Stock Performance

Shares of NAUT stock traded down $0.01 during midday trading on Friday, reaching $0.99. 366,513 shares of the company were exchanged, compared to its average volume of 93,933. Nautilus Biotechnology, Inc. has a 12 month low of $0.93 and a 12 month high of $3.09. The company’s 50 day moving average price is $1.55 and its two-hundred day moving average price is $2.12. The company has a market cap of $124.89 million, a P/E ratio of -1.77 and a beta of 1.25.

Analysts Set New Price Targets

NAUT has been the subject of a number of recent analyst reports. The Goldman Sachs Group cut shares of Nautilus Biotechnology from a “neutral” rating to a “sell” rating and cut their price objective for the company from $2.25 to $1.75 in a report on Thursday, December 5th. Guggenheim set a $2.50 price objective on shares of Nautilus Biotechnology in a research note on Friday, February 28th.

Institutional Trading of Nautilus Biotechnology

Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC increased its position in shares of Nautilus Biotechnology by 56.3% during the 4th quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after purchasing an additional 9,904 shares in the last quarter. Barclays PLC lifted its stake in Nautilus Biotechnology by 79.6% in the 3rd quarter. Barclays PLC now owns 106,174 shares of the company’s stock valued at $303,000 after purchasing an additional 47,059 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in Nautilus Biotechnology during the third quarter worth approximately $67,000. MetLife Investment Management LLC bought a new stake in Nautilus Biotechnology in the 3rd quarter valued at about $87,000. Finally, Palumbo Wealth Management LLC boosted its position in shares of Nautilus Biotechnology by 45.4% during the 4th quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company’s stock worth $48,000 after acquiring an additional 8,888 shares in the last quarter. Institutional investors own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.